Kimberlin, D.W., Acosta, E.P., Sánches, P.J., Sood, S., Agrawal, V., Homans, J., et al. (2008) Pharmacokinetic and Pharmacodynamics Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease. The Journal of Infectious Diseases, 197, 836-845.
https://doi.org/10.1086/528376

has been cited by the following article:

• TITLE: Toxicity and Viral Load in Urine during Valganciclovir Therapy in Premature Infants

  AUTHORS: Merel Boesveld, Henrica L. M. Van Straaten, Marieke A. C. Hemels

  KEYWORDS: CMV, Premature Infants, Valganciclovir, Treatment

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.8 No.8, August 30, 2017

  ABSTRACT: Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age